Semaglutide, 2.0 mg/mL

DRUG2 trials

Sponsors

Novo Nordisk A/S, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes

Phase 1

A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools

CompletedNCT03598621

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2018-07-23End: 2019-01-17Updated: 2020-01-09

Phase 4

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Type 2 Diabetes

Start: 2023-01-01End: 2024-04-30Target: 22Updated: 2023-05-09